Industry News
Pharmaceutical Industry News
After musing on a fall IPO just…
After musing on a fall IPO just last week, Stada is instead being picked up by CapVest Partners in a deal that reportedly values the business at around 10 billion euros ($11.6 billion), according to
Is ‘Microdosing’ Accutane Effective?
Chapped lips, peeling skin, nosebleeds — the drug treats acne, but its side effects can be miserable. Will a lower dose help?
The U.S. subsidiary of India’s…
The U.S. subsidiary of India’s Unichem Pharmaceuticals voluntarily recalled one lot of the muscle relaxant cyclobenzaprine hydrochloride after a labeling snafu.
The FDA has approved a…
The FDA has approved a once-weekly subcutaneous maintenance dose of Leqembi in an autoinjector, dubbed Leqembi IQLIK, which Eisai has hailed as a key milestone in its quest to grow the reach of the Alzheimer's disease
Wegovy’s mechanism of action could…
Wegovy's mechanism of action could be ideal for patients with more moderate disease, according to gastroenterologists and hepatologists surveyed by Spherix.
Flying high after an FDA approval…
Flying high after an FDA approval four months ago to treat generalized myasthenia gravis, Johnson & Johnson’s much-touted Imaavy has taken a hit, coming up short as part of a combination therapy in a rheumatoid
Pfizer is taking a curtain call…
Pfizer is taking a curtain call for Vyndaqel, the low-dose version of its blockbuster tafamidis franchise for the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM).
Amid a growing push for more…
Amid a growing push for more direct-to-consumer access to some of the world’s most popular drugs, Eli Lilly has inked a deal with China’s JD Health to sell its obesity, Type 2 diabetes and alopecia
The University of Michigan is…
The University of Michigan is suing AstraZeneca over claims that the British drugmaker continues to market and sell FluMist despite not renewing a key contract with the school that was crucial to the vaccine's development.
Learn more about how our enhanced…
Learn more about how our enhanced Consumer Audiences can help you achieve more efficient DTC campaigns with audiences created using our synthetic trends methodology.
Patients in the U.S. now have…
Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk’s injected Saxenda (liraglutide).
The Leukemia & Lymphoma…
The Leukemia & Lymphoma Society is marking Blood Cancer Awareness Month by rebranding and rolling out its first national advertising campaign in more than a decade.
The private equity-owned company…
The private equity-owned company held off on a previously planned IPO in March due to market volatility.
After Maze Therapeutics opted not…
After Maze Therapeutics opted not to participate in the National Advertising Division’s self-regulatory process for monitoring promotional claims, a case brought by competitor Vertex Pharmaceuticals is being escalated to federal authorities.
Ahead of plans to raise the price…
Ahead of plans to raise the price of its Type 2 diabetes and obesity blockbuster in the United Kingdom next month, Eli Lilly is temporarily halting Mounjaro orders from the country.
For the second time, the FDA has…
For the second time, the FDA has declined to approve Outlook's anti-VEGF drug for the treatment of wet age-related macular degeneration.
Lawmakers in Virginia have…
Lawmakers in Virginia have approved proposed economic development packages for AstraZeneca and Eli Lilly to locate new manufacturing facilities in the state, according to a report in the Richmond Times-Dispatch.
Fresenius and Charles River…
Fresenius and Charles River Laboratories are among 18 partners that have formed a European Union-supported consortium to develop an automated, hospital-based manufacturing platform for CAR-T therapies.
Roche’s U.S. subsidiary…
Roche’s U.S. subsidiary Genentech broke ground Monday on a $700 million plant tabbed for operation in 2029. The fill-finish plant, which will help produce obesity drugs, is part of Roche’s plan to invest $50 billion
FDA Approves Updated Covid Vaccines With New Restrictions
The agency’s fall recommendations underscore the goals of Health Secretary Robert F. Kennedy Jr. to limit access to the vaccines, which he has long opposed.